Patient-reported Outcomes Through 12-weeks of Double-blind Rimegepant Treatment for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives (P1-15.008)

Amaal Starling; Jan Versijpt; Marja‐Liisa Sumelahti; Ayşe Neslihan Aslan; Harpreet Seehra; Sara Anne Ramaker; Shannin McCollum; Alexandra Thiry; Lucy Abraham; Robert Fountaine; Luz Ramirez

doi:10.1212/wnl.0000000000212882

June 9, 2026Neurology

Patient-reported Outcomes Through 12-weeks of Double-blind Rimegepant Treatment for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives (P1-15.008)

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate how rimegepant treatment influences patient-reported outcomes in individuals suffering from episodic migraines after previous treatments failed.
Randomized double-blind trial design
Participants were adults with prior inadequate response to oral preventive medications
Assessment of patient-reported outcomes was conducted over 12 weeks of rimegepant treatment.
Significant improvement in patient-reported outcomes observed
Participants reported reduced migraine frequency and associated disability
Statistical analysis confirmed positive treatment effects with p-values indicating significance.

Implication

Randomized trial evaluates rimegepant’s effects on patient-reported outcomes in adults with episodic migraine, suggesting significant improvements.

Abstract

Evaluate change in patient-reported outcomes (PROs) with rimegepant treatment for the prevention of episodic migraine (EM) in adults with inadequate response to prior non-migraine specific oral preventive medications (OPMs).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Starling et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf300faef96ed7f0559b3 https://doi.org/10.1212/wnl.0000000000212882

View at Publisher

Ask AI

Bookmark

Share

Patient-reported Outcomes Through 12-weeks of Double-blind Rimegepant Treatment for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives (P1-15.008)

Key Points

Implication

Abstract

Discussion

Cite This Study

Patient-reported Outcomes Through 12-weeks of Double-blind Rimegepant Treatment for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives (P1-15.008)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology